Abstract Library

#4550 The relationship between MEN1 germline mutations and SSTR2 expression in neuroendocrine tumours

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disease characterised by the development of multiglandular parathyroid disease, pituitary tumours, and duodenopancreatic neuroendocrine tumours (NETs). Germline mutations in the tumour suppressor gene MEN1 are the underlying cause. Somatostatin receptor 2 (SSTR2) is commonly expressed by NETs. However, the expression of SSTR2 in patients with MEN1 remains unclear.

Conference:

Presenting Author: Chi Y

Authors: Sun Y, Tan H, Wang H, Shi S, Dong L,

Keywords: multiple endocrine neoplasia type 1, somatostatin receptor 2, neuroendocrine tumour,

#4501 Efficacy and safety of surufatinib in unresectable or metastatic grade 3 neuroendocrine tumours (NET G3): A national multi-centre, retrospective study

Introduction: Currently, there are limited treatment options for NET G3 and therapeutics for NET G1/2 may be considered as alternatives.

Conference:

Presenting Author: Hao J

Authors: Wang J, Zhang N, Liang Y, Long J, Chi Y,

Keywords: surufatinib, NET G3,

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#4440 Efficacy of octreotide in treating advanced gastrointestinal and pancreatic neuroendocrine tumours: A retrospective cohort study

Introduction: Treatment of advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) lacks high-level evidence and remains controversial.

Conference:

Presenting Author: Wang H

Authors: Wang H, Wang Y, Wang C, Wang G, Chi Y,

Keywords: adjuvant therapy, octreotide, gastroenteropancreatic neuroendocrine tumour,

#4429 Liver transplantation for pancreatic neuroendocrine tumour: A case report

Introduction: The use of liver transplantation for metastatic neuroendocrine tumours is still being explored.

Conference:

Presenting Author: Wang H

Authors: Wang H, Tan H, Zhao H, Chi Y,

Keywords: pancreatic neuroendocrine tumour, liver transplantation, STEM,